Laurus Labs Limited (LAURUSLABS.BO)
INR 579.2
(3.34%)
INR 579.2
(3.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.6 Billion INR | -79.68% |
| 2022 | 7.9 Billion INR | -4.52% |
| 2021 | 8.27 Billion INR | -15.87% |
| 2020 | 9.83 Billion INR | 285.31% |
| 2019 | 2.55 Billion INR | 172.25% |
| 2018 | 937.64 Million INR | -44.06% |
| 2017 | 1.67 Billion INR | -11.91% |
| 2016 | 1.9 Billion INR | 42.28% |
| 2015 | 1.33 Billion INR | 95.61% |
| 2014 | 683.69 Million INR | -29.67% |
| 2013 | 972.17 Million INR | 10.2% |
| 2012 | 882.18 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 125.1 Million INR | -83.45% |
| 2024 Q2 | 198.4 Million INR | 58.59% |
| 2023 Q3 | 231.4 Million INR | -37.37% |
| 2023 FY | 1.6 Billion INR | -79.68% |
| 2023 Q2 | 369.5 Million INR | 48.69% |
| 2023 Q1 | 248.5 Million INR | -75.87% |
| 2023 Q4 | 756.1 Million INR | 226.75% |
| 2022 Q3 | 2.03 Billion INR | -12.79% |
| 2022 Q1 | 2.51 Billion INR | 10.69% |
| 2022 Q4 | 1.02 Billion INR | -49.28% |
| 2022 FY | 7.9 Billion INR | -4.52% |
| 2022 Q2 | 2.32 Billion INR | -7.35% |
| 2021 Q4 | 2.27 Billion INR | 47.67% |
| 2021 Q2 | 2.01 Billion INR | -16.36% |
| 2021 Q3 | 1.53 Billion INR | -23.86% |
| 2021 FY | 8.27 Billion INR | -15.87% |
| 2021 Q1 | 2.41 Billion INR | -18.64% |
| 2020 Q2 | 2.42 Billion INR | 41.04% |
| 2020 Q3 | 2.72 Billion INR | 12.62% |
| 2020 Q4 | 2.96 Billion INR | 8.73% |
| 2020 FY | 9.83 Billion INR | 285.31% |
| 2020 Q1 | 1.71 Billion INR | 55.95% |
| 2019 Q4 | 1.1 Billion INR | 49.93% |
| 2019 Q1 | 151 Million INR | -65.03% |
| 2019 Q2 | 565.5 Million INR | 274.5% |
| 2019 Q3 | 734.7 Million INR | 29.92% |
| 2019 FY | 2.55 Billion INR | 172.25% |
| 2018 Q1 | 165.58 Million INR | -63.27% |
| 2018 FY | 937.64 Million INR | -44.06% |
| 2018 Q4 | 431.79 Million INR | 142.35% |
| 2018 Q3 | 178.17 Million INR | 9.91% |
| 2018 Q2 | 162.1 Million INR | -2.1% |
| 2017 Q3 | 348.7 Million INR | -28.48% |
| 2017 Q4 | 450.8 Million INR | 29.28% |
| 2017 FY | 1.67 Billion INR | -11.91% |
| 2017 Q1 | 389.05 Million INR | -45.46% |
| 2017 Q2 | 487.55 Million INR | 25.32% |
| 2016 Q1 | 256.43 Million INR | 0.0% |
| 2016 Q4 | 713.33 Million INR | 58.45% |
| 2016 FY | 1.9 Billion INR | 42.28% |
| 2016 Q3 | 450.19 Million INR | -6.76% |
| 2016 Q2 | 482.81 Million INR | 88.28% |
| 2015 FY | 1.33 Billion INR | 95.61% |
| 2014 FY | 683.69 Million INR | -29.67% |
| 2013 FY | 972.17 Million INR | 10.2% |
| 2012 FY | 882.18 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 73.929% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 94.94% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 65.905% |
| Granules India Limited | 4.05 Billion INR | 60.388% |
| Indoco Remedies Limited | 984.6 Million INR | -63.061% |
| Achyut Healthcare Limited | 5.73 Million INR | -27909.421% |
| Ajanta Pharma Limited | 8.16 Billion INR | 80.329% |
| Alkem Laboratories Limited | 17.95 Billion INR | 91.06% |
| Alpa Laboratories Limited | 167.76 Million INR | -856.993% |
| Brooks Laboratories Limited | -195.91 Million INR | 919.471% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 0.594% |
| Bajaj HealthCare Limited | -837.93 Million INR | 291.603% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -112.778% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 97.117% |
| Eris Lifesciences Limited | 3.91 Billion INR | 59.042% |
| FDC Limited | 3.05 Billion INR | 47.399% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 110.691% |
| Gufic Biosciences Limited | 861.35 Million INR | -86.392% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 61.861% |
| Ipca Laboratories Limited | 5.47 Billion INR | 70.668% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -614.731% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 913.801% |
| Lasa Supergenerics Limited | -217.3 Million INR | 838.82% |
| Lupin Limited | 19.14 Billion INR | 91.614% |
| Mankind Pharma Limited | 19.12 Billion INR | 91.607% |
| Medicamen Biotech Limited | 109.31 Million INR | -1368.759% |
| Medico Remedies Limited | 82.9 Million INR | -1836.46% |
| Megasoft Limited | -127.46 Million INR | 1359.552% |
| NATCO Pharma Limited | 13.88 Billion INR | 88.435% |
| Piramal Pharma Limited | 178.2 Million INR | -800.954% |
| RPG Life Sciences Limited | 876.6 Million INR | -83.151% |
| Sigachi Industries Limited | 571.8 Million INR | -180.779% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 98.323% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 46.533% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -534.229% |
| Unichem Laboratories Limited | -704.74 Million INR | 327.814% |
| Wanbury Limited | 559.56 Million INR | -186.92% |
| Windlas Biotech Limited | 581.87 Million INR | -175.921% |
| ZIM Laboratories Limited | 172.46 Million INR | -830.919% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 95.84% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 141.463% |
| Divi's Laboratories Limited | 16 Billion INR | 89.966% |
| Hester Biosciences Limited | 188.89 Million INR | -749.966% |
| Procter & Gamble Health Limited | 2 Billion INR | 20.116% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -256.995% |
| Bal Pharma Limited | 73.92 Million INR | -2071.884% |
| Strides Pharma Science Limited | -706.14 Million INR | 327.363% |
| Venus Remedies Limited | 284.9 Million INR | -463.515% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 25.98% |
| Nectar Lifesciences Limited | 49.95 Million INR | -3114.214% |
| Shilpa Medicare Limited | 318.74 Million INR | -403.699% |
| Aarti Drugs Limited | 1.71 Billion INR | 6.34% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -19.43% |
| Suven Life Sciences Limited | -1.05 Billion INR | 252.794% |
| Ind-Swift Limited | 142.31 Million INR | -1028.147% |
| Valiant Laboratories Limited | 3.19 Million INR | -50134.668% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 70.948% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 128.296% |
| Themis Medicare Limited | 435.23 Million INR | -268.879% |
| Hikal Limited | 696.02 Million INR | -130.669% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 90.307% |
| Sequent Scientific Limited | -358.69 Million INR | 547.601% |
| Novartis India Limited | 851.9 Million INR | -88.461% |
| Wockhardt Limited | -4.63 Billion INR | 134.676% |
| Jubilant Pharmova Limited | 771 Million INR | -108.236% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -22538.184% |
| Neuland Laboratories Limited | 3 Billion INR | 46.497% |
| Morepen Laboratories Limited | 961.59 Million INR | -66.961% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -999.552% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 1869.79% |